Amneal Pharmaceuticals, Inc. $AMRX Stock Holdings Increased by Odyssean LLC

Posted by Brenda Bartman on Sep 5th, 2026

Odyssean LLC grew its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 62.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 183,507 shares of the company’s stock after buying an additional 70,589 shares during the period. Odyssean LLC owned about 0.06% of Amneal Pharmaceuticals worth $3,177,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Public Employees Retirement System of Ohio bought a new position in Amneal Pharmaceuticals during the second quarter worth $29,000. Kemnay Advisory Services Inc. bought a new stake in Amneal Pharmaceuticals during the fourth quarter valued at $26,000. Federated Hermes Inc. raised its holdings in shares of Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Transamerica Financial Advisors LLC raised its holdings in shares of Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. Finally, Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Insider Activity

In other news, EVP Jason Daly sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. The trade was a 85.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president directly owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 413,016 shares of company stock valued at $7,216,567. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Stock Down 2.4%

Amneal Pharmaceuticals stock opened at $17.44 on Friday. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. Amneal Pharmaceuticals, Inc. has a one year low of $9.44 and a one year high of $19.26. The company has a 50-day simple moving average of $17.76 and a 200-day simple moving average of $14.96. The firm has a market capitalization of $5.57 billion, a P/E ratio of 35.59 and a beta of 1.24.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on AMRX. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $22.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, August 26th. The Goldman Sachs Group restated a “buy” rating and issued a $21.00 target price on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. UBS Group upped their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $19.00.

Check Out Our Latest Stock Report on AMRX

Amneal Pharmaceuticals Company Profile

(Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.